Unlike other biotech and pharma companies, TAVARGENIX acts as a think tank, relying on its own proprietary expertise in TKTL1 biology and drug discovery as well as on its extensive network of biotech companies and academia. This drug architect-like structure leads to low overhead costs, allowing TAVARGENIX to invest a major part of its resources in research and development.

Mission and Vision

The company’s primary focus is cancer treatment, particularly targeting the changed metabolism of aggressive cancer cells. TAVARGENIX aims to bring the first drug to market that blocks the activity of the protein TKTL1 in order to stop the aggressiveness and invasiveness of tumor cells over-expressing TKTL1. In addition, TKTL1 related diagnostic procedures are used to select patients with high probability of therapy success, to follow up in case the treatment is effective and to detect a possible relapse very early on. This way, TAVARGENIX will change the usual way to treat cancer.


In 2006, the pharma company TAVARGENIX was founded by Dr. Johannes Coy as a spin-off from r-biopharm AG. Since then, TAVARGENIX has been developing small molecule inhibitors of the target enzyme TKTL1 to treat aggressive cancer cells. TAVARGENIX is funded by the German Federal Ministry of Education and Research (BMBF) project “KMU-innovativ”: Biotechnologie – BioChance (“Transketolase TKTL1 – a new target for the treatment of cancer”; RN: 0315364) and by private investors.


Due to the COVID pandemic in early 2020, TAVARGENIX started to expand research in order to explore the links between TKTL1 and SARS-CoV-2. Latest research has led to some very promising approaches to contain the spread of COVID-19 as well as treating patients effectively. TAVARGENIX is now following up these approaches in further studies.